Organic Process Research & Development · 2004 · 37 citations · 15 references
PharmacyMedicinal ChemistryPharmacologyDrug DiscoveryPharmaceutical ManufacturingSynthetic Medicinal ChemistryHigh-throughput SynthesisProcess SynthesisChiral Product SynthesisEnantioselective SynthesisNatural Product SynthesisSmall-molecule Library ConstructionSmall-scale Manufacturing
The development of a novel, cost-effective synthesis of the vitronectin receptor antagonist SB-273005 became necessary as the compound proceeded to Phase 1. A practical synthesis of the compound presented challenges to the process chemist. Chief among the challenges was developing an enantioselective route to the compound. Second was either developing a scalable Mitsunobu coupling of the side chain to the main body or finding alternate chemistry. In this paper we will describe the chemistry we developed which allowed us to make over a hundred kilograms of SB-273005 by a process that we believe is suitable for even larger scale manufacturing.
15
V. Wayne Engleman, G. Allen Nickols, F. Patrick Ross et al. · Journal of Clinical Investigation · 1997 · 287 citations · Full text
J.‐P. GENET, Catherine Pinel, Virginie Ratovelomanana‐Vidal et al. · Tetrahedron Asymmetry · 1994 · 175 citations
Inhibition of integrin function by a cyclic RGD-containing peptide prevents neointima formation.
Hiroyuki Matsuno, J M Stassen, J. Vermylen et al. · Circulation · 1994 · 170 citations